The AIR's Knocked Out of Alkermes

Drug developer Alkermes (Nasdaq: ALKS  ) announced yesterday that it would be slimming down its operations and cutting jobs. This decision followed the shuttering of its phase 3 AIR inhaled-insulin program with Eli Lilly (Nasdaq: LLY  ) .  

Last week, Lilly became the last of the three big pharmas with inhaled-insulin programs to close down its work in that area. Novo Nordisk (NYSE: NVO  ) stopped its inhaled-insulin program (at least temporarily) in January, and Pfizer (NYSE: PFE  ) terminated its inhaled-insulin program after recording miserable sales of Exubera in the nearly two years it was on the market. 

Lilly and Alkermes had been working together on AIR insulin since 2001 and had been testing their AIR inhaled-insulin program in phase 3 trials since 2005. The announcement last week eliminated the need for Alkermes to use its manufacturing facility to supply this drug for clinical testing and future commercial use, which led to the layoffs and cost-cutting at the company.

As with its very similar drug-delivery counterpart, Nektar Therapeutics (Nasdaq: NKTR  ) (Pfizer's Exubera partner that got the boot), there is still a lot to like about Alkermes -- even with the failure of its AIR insulin program and the slow sales growth of its Vivitrol alcohol-dependence treatment. For instance, Alkermes received a bit of competitive good news when Eli Lilly's extended-release Zyprexa failed to get regulatory approval last month.

Lilly was a partner with Alkermes for AIR insulin and an extended-release diabetes drug, but Lilly's long-acting Zyprexa antipsychotic drug would have competed (probably very effectively) with Risperdal Consta, from Johnson & Johnson and Alkermes. Now that Alkermes doesn't have to worry about having its royalty revenue growth smacked down thanks to long-acting Zyprexa, and now that the company has cut some of its spending, we could be in for a nice earnings-forecast treat when Alkermes updates its fiscal 2009 guidance in May.


Read/Post Comments (0) | Recommend This Article (3)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 603795, ~/Articles/ArticleHandler.aspx, 10/25/2014 6:41:13 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated 9 hours ago Sponsored by:
DOW 16,805.41 127.51 0.76%
S&P 500 1,964.58 13.76 0.71%
NASD 4,483.72 30.92 0.69%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

10/24/2014 3:59 PM
ALKS $45.91 Up +0.63 +1.39%
Alkermes, Inc. CAPS Rating: ***
NKTR $13.15 Down -0.10 -0.75%
Nektar Therapeutic… CAPS Rating: **
NVO $45.77 Up +0.05 +0.11%
Novo Nordisk CAPS Rating: *****
PFE $29.11 Up +0.51 +1.78%
Pfizer CAPS Rating: ****

Advertisement